Drugs / Dibotatug
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06766864 | Mar → Aug 2025 | — | Dren Bio | Completed | No outcome recorded |
| Phase 1 | NCT06602232 | Oct 2024 → May 2027 expected | alopecia areata, vitiligo | Dren Bio | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07712562 | Aug 2026 → Apr 2029 expected | aplastic anemia, bone marrow failure syndrome | Dren Bio | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05475925 | Jul 2022 → Dec 2026 expected | T-cell large granular lymphocyte leukemia, aggressive NK-cell leukemia, enteropathy-associated T-cell lymphoma, extranodal nasal NK/T cell lymphoma +9 | Dren Bio | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT07647627 Background | — | — | Dren Bio | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dibotatug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07712562 ↗ |
| Known as | DR-01 | “Dibotatug (DR-01) administered by IV infusion” NCT07712562 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody” NCT05475925 ↗ |
| Route | Intravenous | “administered via IV infusion” NCT06602232 ↗ |